Ligand Pharmaceuticals reported consistent financial performance in Q1 2026, underpinned by royalties from partner product sales and contract revenue. The company’s recent acquisition of XOMA Royalty expands its biopharma royalty portfolio, enhancing revenue diversification amid regulated industry dynamics. Ligand’s business model centers on leveraging licensing agreements, royalties, and Captisol sales, supported by strong counterparty credit management and liquidity. Key growth drivers include expanding royalty streams via strategic investments and new product approvals from partners. Risks stem primarily from dependency on partner sales, regulatory uncertainty, and supply chain concentration for Captisol production.